A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Recruiting

Phase 1

ASP2138 with Cancer TreatmentsA Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Sponsor:

Astellas Pharma Global Development, Inc.

Code:

NCT05365581

Conditions

Gastric Adenocarcinoma

Gastroesophageal Junction (GEJ) Adenocarcinoma

Pancreatic Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ASP2138

Pembrolizumab

Oxaliplatin

Leucovorin

Fluorouracil

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Astellas Pharma Global Development, Inc. on 2025-04-23.